


THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES



The Prevention and Treatment of Cardiovascular Diseases

No. of Pages: 372

ISBN: 978-1-78021-026-1 (eBook)

ISBN: 978-1-78021-526-6 (Print Volume)

For more information of e-book and Print Volume(s) order, please [click here](#) Or contact : eolssunesco@gmail.com

Preface**vii****Flaxseed in Cardiovascular Health and Disease****1**

Kailash Prasad, *Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada*

1. Introduction
2. Flaxseed and its Components
3. Pharmacological Activity of Flaxseed and its Components
4. Mechanism of Atherosclerosis
5. Flaxseed and its Components on Mechanism of Atherosclerosis
 - 5.1. Antioxidant Activity of Flaxseed and Its Components
 - 5.2. Flaxseed and Its Components on Inflammatory Mediators
 - 5.3. Flaxseed and Components, Chemokines and Cell Adhesion Molecules
 - 5.4. Flaxseed Components and Monocyte Colony Stimulating Factor (MCSF) and Foam Cells
 - 5.5. Flaxseed Components and Growth Factors
 - 5.6. Flaxseed Components and Platelet Aggregation
6. Flaxseed and its Components on Risk Factors for Atherosclerosis
 - 6.1. Serum Lipids
 - 6.1.1. Flaxseed
 - 6.1.2. Flaxseed with Very Low α -Linolenic Acid (CDC-Flaxseed)
 - 6.1.3. Flaxseed Oil
 - 6.1.4. SDG
 - 6.1.5. Flax Lignan Complex (FLC)
 - 6.2. Hypertension
 - 6.3. Diabetes
7. Flaxseed and its Components and Atherosclerosis
 - 7.1. Suppression of Atherosclerosis
 - 7.1.1. Flaxseed and Suppression of Atherosclerosis
 - 7.1.2. CDC-flaxseed and Suppression of Atherosclerosis
 - 7.1.3. Flaxseed Oil and Suppression of Atherosclerosis
 - 7.1.4. SDG and Suppression of Atherosclerosis
 - 7.1.5. FLC and Suppression of Atherosclerosis
 - 7.2. Slowing of Progression of Atherosclerosis
 - 7.3. Regression of Atherosclerosis
 - 7.3.1. SDG and Regression of Atherosclerosis
 - 7.3.2. FLC and Regression of Atherosclerosis
8. Health Benefits
9. Side Effects of Flaxseed and its Components
10. Conclusion

Carotid Endarterectomy**31**

John B. Chang, *Director, Long Island Vascular Center, Roslyn, New York, U.S.A.*

Robert W. Chang, *The Permanente Medical Group, South San Francisco, California, U.S.A.*

1. Introduction
 - 1.1. Historical Background Leading to Current Randomized Studies
 - 1.2. Randomized Clinical Trials examining Carotid Endarterectomy
 - 1.3. Carotid Endarterectomy – Surgical Technique
 - 1.4. Trials comparing Carotid Artery Stenting with Carotid Endarterectomy
 - 1.5. Conclusion

Abdominal Aortic Aneurysms

62

Chuo Ren Leong, Rajeev Gupta, Mark Kissin, *Long Island Jewish Medical Center, New Hyde Park, New York, U.S.A.*

Robert W. Chang, *The Permanente Medical Group, South San Francisco, California, U.S.A*

John B. Chang, *Long Island Jewish Medical Center, New Hyde Park, New York, U.S.A.*

1. Introduction
 - 1.1. Historical Background
 - 1.2. Abdominal Aortic Aneurysms
 - 1.3. Anatomy
 - 1.4. Pathophysiology
 - 1.5. Etiology
 - 1.6. Diagnosis
 - 1.7. Surgical Treatment
 - 1.8. Indications for Repair
 - 1.9. Open Repair
 - 1.10. Endovascular Repair of Abdominal Aortic Aneurysm
 - 1.11. Open Arterial Access Technique
 - 1.12. Endovascular Repair of Proximal Abdominal Aortic Aneurysm
 - 1.12.1. Renal Stents
 - 1.12.2. Snorkel Technique to Revascularize Internal Iliac Arteries
 - 1.13. Iliac Conduit for EVAR for Severe Occlusive Disease at the External Iliac Arteries
 - 1.14. Fenestrated Stents
 - 1.15. Branched Stents
 - 1.16. Non-Resective Repair of AAA (Hacker et al 2011)
 - 1.17. Recent Studies
 - 1.18. Short Term Results of EVAR
 - 1.19. DREAM Trial (Prinssen et al 2004)
 - 1.20. DREAM Follow-Up (Blakensteijn et al 2005)
 - 1.21. Dream Update (De Bruin et al 2010)
 - 1.22. EVAR 1 Trial (Greenhalgh et al 2004)
 - 1.23. EVAR 1 Trial Follow-Up (Greenhalgh et al 2005)
 - 1.24. EVAR 1 Long-Term Results (Greenhalgh et al 2010)
 - 1.25. EVAR 2 Trial (EVAR trial participants. 2007)
 - 1.26. Eurostar Registry (Harris et al 2000; Laheij et al 2000)
 - 1.27. Current FDA-Approved Endografts for AAA
 - 1.28. Personal Data
 - 1.29. Endovascular Repair of an Iliac Artery Aneurysm
 - 1.30. Endovascular Procedures in Azotemic Condition Using CO₂.
 - 1.31. Conclusion

Management of Chronic Ischemia of the Lower Limbs

97

Daniel Kassavin, *Northshore-LIJ Healthcare System, New Hyde Park, New York, U.S.A.*

Robert W. Chang, *Attending Vascular Surgeon, The Permanente Medical Group, South San Francisco, California, U.S.A.*

Mark Kissin, *Attending Vascular Surgeon, Northshore-LIJ Health Care System, New Hyde Park, New York, U.S.A.*

John B. Chang, *Attending Vascular Surgeon, Northshore –LIJ Health Care System, New Hyde Park, New York, U.S.A.*

Professor, Clinical Surgery, Hofstra Northshore-LIJ School of Medicine, Uniondale, New York, U.S.A.

Adjunct Professor, Clinical Surgery, Albert Einstein College of Medicine, Bronx, New York, U.S.A.

Director, Long Island Vascular Center, Roslyn, New York, U.S.A

1. Introduction
2. Incidence
3. Disease Progression
4. Risk Factors and Management
 - 4.1. Smoking

- 4.2. Diabetes
- 4.3. Dyslipemia
- 4.4. Hypertension
- 4.5. Exercise
- 4.6. Chronic Renal Insufficiency
5. Pharmacotherapy
6. History and Physical
 - 6.1. Claudication
 - 6.2. Critical Limb Ischemia
7. Diagnostics
 - 7.1. Non-Invasive Studies
 - 7.2. Imaging: Duplex Ultrasound, CTA, MRA, and Angiography
 - 7.3. TASC Classification
8. Treatment
 - 8.1. Endovascular and Open Surgical Options and Outcomes
 - 8.2. Angioplasty/Stent Procedures for Aorto-Iliac Occlusive Diseases
 - 8.3. Bypass and Other Complex Procedures for Aortic Occlusive Diseases
 - 8.4. Endovascular Procedures and Bypasses for Lower Limb Ischemia
 - 8.5. Graft Infection
9. Conclusion

Carotid Artery Stent and Medical Management of Carotid Disease

172

Wei Zhou, MD, FICA, *Division of Vascular and Endovascular Surgery, Stanford University, Stanford, California, U.S.A.*

1. Carotid Disease
2. Carotid Artery Stenting
 - 2.1. Pre-operative Evaluation of Carotid Artery Stenting
 - 2.2. Techniques of Carotid Artery Stenting
 - 2.3. Post-operative Management
 - 2.4. Clinical Outcome of Carotid Artery Stenting
 - 2.5. Management of CAS-associated Complications
3. Medical Management
4. Guideline Approaches

Management of Subclavian Vein Thrombosis Known as Paget-Schroetter Syndrome

196

J. Ernesto Molina, University of Minnesota, Minneapolis, Minnesota, U.S.A.

1. Definition
2. Anatomy of the obstructing site
3. Diagnosis
4. Immediate therapy
 - 4.1. Heparin
5. Thrombolysis
6. Surgical treatment
7. The operation
8. Post operative assessment
9. Post operative care
10. Suboptimal, Ineffective, or Wrong Treatments
11. Other Surgical Procedures
 - 11.1 The Transaxillary Surgical Route
 - 11.2 The Paraclavicular Approach
12. Conclusions

Current Management of Major Upper and Lower Extremity Vascular Trauma 207

Randall W. Franz, *Ohio Health, Columbus, Ohio, U.S.A.*

Evan T. Franz, *University of Cincinnati, Cincinnati, Ohio, U.S.A.*

1. Introduction
2. General Management of Upper and Lower Extremities
3. Surgical Management of Arterial Injuries
4. Medical Management of Arterial Injuries
5. Diagnostic Imaging
6. Associated Orthopedic Injuries
7. Venous Injury Repair
8. Fasciotomy
9. Upper Extremity Nerve Injuries
10. Soft-Tissue Deficits
11. Amputation
12. Forearm Arterial Injuries
13. Proximal Upper Extremity Arterial Injuries
14. Femoral Arterial Injuries
15. Popliteal Arterial Injuries
16. Below-Knee Arterial Injuries
17. Endovascular Treatment
18. Discussion
19. Conclusion

Vascular Embolization: Indications, Materials and Techniques 230

Chris C. Sung and David N. Siegel, *Long Island Jewish Medical Center, New Hyde Park, New York, U.S.A.*

1. Introduction
 - 1.1. Background
 - 1.2. History
2. Permanent Large Embolic Agents
 - 2.1. Coils
 - 2.2. Amplatzer Vascular Plug
 - 2.3. Detachable Balloons
3. Permanent Small Embolic Agents
 - 3.1. Polyvinyl Alcohol Particle
 - 3.2. PVA Microspheres
 - 3.3. Tris-Acryl Microspheres
 - 3.4. Hydrogel - Polyzene F Microspheres
 - 3.5. Drug – Eluting Microspheres
 - 3.6. Radioactive Microspheres
4. Liquid Embolic Agents
 - 4.1. Absolute Alcohol
 - 4.2. Sodium Tetradecyl Sulfate
 - 4.3. N – Butyl Cyanoacrylate
 - 4.4. Ethylene Vinyl Alcohol/Dimethyl Sulfoxide
 - 4.5. Lipiodol
5. Temporary Embolic Agents
 - 5.1. Autologous Blood Clot
 - 5.2. Gelatin Sponge
 - 5.3. Avitene
6. Techniques and Equipment
7. Conclusion

Endovascular Repair of The Thoracic Aorta**240**Frank Manetta, *Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York, USA*

1. Introduction
2. Evolution of Endovascular Technology
 - 2.1. Early Trials
 - 2.2. Commercial Devices
 - 2.2.1. W.L. Gore TAG
 - 2.2.2. Medtronic Talent and Valiant Thoracic Endoprostheses
 - 2.2.3. Cook Zenith TX2 Endoprosthesis
 - 2.3. Emerging Technologies
 - 2.4. Indications for Use
3. Aortic Pathology Treated with Endovascular Grafting
 - 3.1. Descending Thoracic Aneurysms
 - 3.2. Penetrating Ulcers and Aortic Pseudoaneurysms
 - 3.3. Aortic Dissection
 - 3.3.1. Clinical Presentation
 - 3.4. Traumatic Aortic Injury
 - 3.5. Coarctation of the Aorta
 - 3.6. Aorto-bronchial and Aorto-esophageal Fistula
4. Operative Strategies for Endovascular Grafting
 - 4.1. Preoperative Planning
 - 4.2. Imaging
 - 4.3. Anesthesia Considerations
 - 4.4. Spinal Cord Protection
 - 4.5. Operative Environment
 - 4.6. Operative Technique
 - 4.6.1. Vascular Access
 - 4.6.2. Device Placement
 - 4.6.3. Hybrid Procedures
5. Complications of Endovascular Grafting
 - 5.1. Endoleak
 - 5.2. Endograft Collapse
 - 5.3. Retrograde Aortic Dissection
 - 5.4. Stroke
 - 5.5. Spinal Cord ischemia
 - 5.6. Visceral Ischemia
 - 5.7. Access Complications
 - 5.8. Aorto-Esophageal and Aorto-Bronchial Fistula
 - 5.9. Graft Infection
 - 5.10. Post-Implantation Syndrome
 - 5.11. Device Migration
6. Overall Outcomes
 - 6.1. Societal and Economic Cost
7. Conclusions

Management of Valvular Heart Disease - Surgical Perspective**276**

Bijoy G Rajbanshi, MD, Yale University School of Medicine, New Haven, Connecticut, USA, Consultant Cardiac Surgeon, Shahid Ganganal National Heart Center, Kathmandu, Nepal

John A Elefteriades, MD, FICA, William W.L. Glenn Professor of Cardiothoracic Surgery, and Director of the Aortic Institute, Yale University School of Medicine, and Yale New Haven Hospital, New Haven, Connecticut, USA

1. Introduction
2. Pathophysiology of Regurgitant and Stenotic Lesions
3. Aortic Valve
 - 3.1. Aortic Valve Stenosis
 - 3.2. Aortic Valve Regurgitation

- 3.3. Surgery for Aortic Valve Disease
- 4. Mitral Valve
 - 4.1 Mitral Valve Regurgitation
 - 4.2. Mitral Valve Stenosis
 - 4.3. Surgery for Mitral Valve Disease
- 5. Tricuspid Valve
 - 5.1. Tricuspid Valve Regurgitation
 - 5.2. Tricuspid Valve Stenosis
 - 5.3. Surgery for Tricuspid Valve Disease
- 6. Pulmonary Valve
- 7. Infective Endocarditis

Index **311**

About EOLSS **317**